Physician profile
Hung Nguyen
NPI 1255590444
$6,427.31
in general payments reported to CMS, 2019-2025
27 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $450 · 2021: $829 · 2022: $1,021 · 2023: $1,030 · 2024: $1,239 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,371.07 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $1,337.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $1,188.54 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $760.50 | 2019-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $387.78 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $202.82 | 2019-2022 | |
| Insulet Corporation | $171.87 | 2025 | Omnipod, Omnipod |
| Covidien LP | $128.28 | 2019 | |
| Xeris Pharmaceuticals, INC. | $126.26 | 2021-2024 | Gvoke Hypopen, Keveyis |
| Radius Health, INC. | $96.26 | 2019-2023 | Tymlos |
| Medtronic, INC. | $92.85 | 2021 | |
| Merck Sharp & Dohme LLC | $73.41 | 2020-2021 | |
| Abbvie INC. | $72.64 | 2019-2021 | |
| Zealand Pharma US, INC. | $54.52 | 2021 | |
| Medtronic Minimed, INC. | $54.08 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $53.53 | 2021-2023 | Korlym |
| Beta Bionics, INC. | $42.27 | 2023 | Ilet Bionic Pancreas |
| Amgen INC. | $32.83 | 2019 | |
| Zyla Life Sciences, INC. | $29.92 | 2020 | |
| Becton, Dickinson and Company | $26.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $24.91 | 2019 | |
| Lifescan, INC. | $22.23 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.41 | 2021 | |
| Vistapharm, INC. | $13.61 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.62 | 2022 | |
| Pfizer INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.